BioSpace News Archive

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that initial data from its ongoing Phase 1 dose-escalation study of tidutamab (XmAb ® 18087), an SSTR2 x CD3 bispecific antibody, in patients with neuroendocrine tumors (NETs) will be presented during the upcoming North American Neuroendoc

AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a company focused on developing and commercializing innovative therapeutics for human aging, and Lineage Cell Th

Kinnate Biopharma Inc., a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically-defined cancers, today announced the appointment of Dean J. Mitchell as board Chairman. Mr. Mitchell is an accomplished executive who brings more than three decades of experience in the biophar

Schwazze, formerly operating as Medicine Man Technologies Inc. (OTCQX: SHWZ) (“Schwazze " or “the Company”), today announced executive and Board appointments that will accelerate growth and continue to build operational capabilities for the Company.

Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update regarding the Company’s Wand® dental business, as well as the commercial roll-out of its CompuFlo® Epidural System and CathCheck™ technology.

Yulong Eco-Materials Limited (OTC PINK:YECO ) today announced that it intends to build an incubator laboratory for development of cell and extracellular vesicle (EV) based therapeutics.

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that management will present a corporate overview at H.C. Wainwright’s 22 nd Annual Global Investment Conference. Event details follow: Date: Tuesday, September 15 th Time: 2:30 p.m. Eastern Time Webcast: https://www.CassavaSciences.com/company-presentations Cassava Sciences’ virtual public

SQI Diagnostics, Inc. (TSX-V: SQD; OTCQX-US: SQIDF), a precision medicine company that discovers, develops, manufactures and commercializes innovative rapid diagnostic testing for healthcare professionals, patients and consumers worldwide, today announced it is expanding its proprietary rapid diagnostic testing portfolio targeting organ transplant, autoimmune disease and serological testing.

Partnerships will help advance the Lung Association’s COVID-19 Action Initiative to Support Communities Hit Hardest

In a long and distinguished career, Bonner has worked tirelessly to bring new innovations to patients that improve outcomes and quality of care